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ORIGINAL ARTICLE
Association between DNA methylation of HSPB1 and death in
low Gleason score prostate cancer
N Vasiljevic´1, AS Ahmad1, C Beesley2, MA Thorat1, G Fisher1, DM Berney3, H Møller4, Y Yu5, Y-J Lu3, J Cuzick1, CS Foster2 and AT Lorincz1
BACKGROUND: Heat shock protein 27 (Hsp-27) encoded by gene HSPB1 is a critical regulator of the behavioral phenotype of
human prostate cancer (PCa) cells, enhanced expression being associated with highly aggressive disease and poor clinical outcome.
In contrast, the protein is not expressed in PCas of low malignant potential. To gain insight into the mechanism regulating its
expression, we tested the hypothesis that differential methylation of CpG islands within HSPB1 controls transcription and
subsequent translation of the gene.
METHODS:We studied prostate epithelial cell lines and tissue biopsies, including 59 BPH and 415 PCas, of which 367 were a cohort
of men with up to 20 years of follow-up. Methylation across the gene (DNA methylation (DNAme)) was assayed by pyrosequencing.
Hsp-27 expression was assessed by western blot and immunohistochemistry.
RESULTS: In cancer tissues, methylation increased in a 30 direction (Po0.0001) whereas in benign hyperplasia methylation was
constantly below 5%, a cutoff giving a speciﬁcity of 100% and sensitivity of 50%. Although methylation of the promoter region was
signiﬁcantly discriminating between benign and malignant prostatic epithelia, it compared poorly with methylation of the ﬁrst
intron. The prognostic value of HSPB1 DNAme was conﬁrmed by both univariate (hazard ratio 1.77 per 50% increment, P¼ 0.02)
and multivariate models. Interaction between HSPB1 methylation and Gleason score revealed high DNAme to be a reliable
prognostic marker of poor outcome in men with low Gleason score (P¼ 0.014).
CONCLUSIONS: Our data indicate CpG methylation of the ﬁrst HSPB1 intron to be an important biomarker that identiﬁes aggressive
PCas otherwise regarded as low risk by current clinical criteria but that, biologically, require immediate active management.
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INTRODUCTION
Heat shock protein 27 (Hsp-27), encoded by the gene HSPB1
located on chromosome 7q11.23 has been shown in several
independent studies to be a reliable biomarker of poor clinical
outcome in human prostate cancer (PCa)1–4 as well as in human
breast cancer,5 colorectal cancer6 and malignant melanoma.7
Biologically, Hsp-27 is an anti-apoptotic protein8,9 that induces
intracellular homeostasis and allows cellular repair and recovery
after physical and chemical insults.10 Although Hsp-27 is
constitutively expressed in most human cells, induced
overexpression during carcinogenesis can lead to increased
survival of the malignant cells. Therefore, it is not surprising that
studies link high expression of Hsp-27 to unfavorable prognosis in
many cancer types.2,11–13 The prognostic potential has been
conﬁrmed in prostate cell lines14 as well as in prostate tissues
where overexpression has been linked with hormone resistance
and poor clinical outcome.1,2,15 During early prostate
carcinogenesis, expression of Hsp-27 protein becomes
universally abrogated but may be re-expressed subsequently, in
which case the malignancy develops an aggressive phenotype.1,2
Although the speciﬁc factors controlling these changes are
presently unknown, one plausible mechanism is DNA
methylation (DNAme) of the HSPB1 gene. The majority of CpG
dyads in the human genome are methylated with the exception of
CG-rich regions called CpG islands.16 CpG islands mainly cover
gene promoters and ﬁrst exons and their hypermethylation is
associated with repressed transcription of many tumor-suppressor
genes.17,18 Therefore, we test the hypothesis that the DNAme
status of HSPB1, particularly the HSPB1 promoter, exon and intron
regions, is an important determinant of PCa behavior. Thereafter,
we assess any potential relationship between DNAme and Hsp-27
protein levels. Our objectives are also to investigate the diagnostic
biomarker potential, by comparing the methylation status of
BPH vs PCa, and the prognostic potential of DNAme, by analyzing
the association between the methylation and PCa-speciﬁc death
in the well-characterized Transatlantic Prostate Group (TAPG)
cohort.19
MATERIALS AND METHODS
Human prostate tissue specimens and cell lines
Fresh frozen prostate biopsies from 77 patients, 48 PCa and 29 BPH, were
used and have been previously described in detail.20 Formalin-ﬁxed
parafﬁn-embedded (FFPE) PCa biopsies from a deﬁned subset of 388
patients were randomly selected from a large cohort with TURP of well-
characterized men residing in the United Kingdom—the TAPG cohort.19,21
Sixteen patients were excluded because of poor DNA quality and ﬁve
because of only normal tissue being available, leaving 367 specimens
1Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK; 2Department of Cellular Pathology and Molecular
Genetics, University of Liverpool, Liverpool, UK; 3Molecular Oncology Centre, Barts Cancer Institute, Queen Mary University of London, London, UK; 4King’s College London,
Thames Cancer Registry, London, UK and 5Department of Pathology, Changhai Hospital, The Second Military Medical University, Shanghai, China. Correspondence: Professor
AT Lorincz, Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.
E-mail: a.lorincz@qmul.ac.uk
Received 6 August 2012; revised 11 September 2012; accepted 1 October 2012; published online 20 November 2012
Prostate Cancer and Prostatic Disease (2013) 16, 35–40
& 2013 Macmillan Publishers Limited All rights reserved 1365-7852/13
www.nature.com/pcan
eligible. A total of 30 FFPE BPH specimens were collected after TURP at
St Bartholomew’s Hospital, London during the period 2003–2005.
Human prostate cell lines obtained from ATCC (Rockville, MD, USA) were
the PNT2 immortalized epithelial cell line, the hormone-sensitive cancer
cell lines LNCaP and VCaP and the hormone resistant, strong tumorigenic
cancer cell lines DU145, PC3, PC3M and PC3M3 as well as PC3M variant cell
line ST3 with silenced RLP19. Cell lines were cultured as previously
described.22
For the population-based retrospective TAPG cohort UK national ethical
approval was obtained from the Northern Multicentre Research Ethics
Committee followed by local ethics committee approvals from each of the
collaborating hospital trusts.19 For all other tissues, written informed
consent was obtained from all patients. Ethical approval was obtained
from East London and the City REC Alpha and from Changhai Hospital
Ethics Committee.
DNA extraction and bisulﬁte conversion
DNA from frozen tissues was extracted and bisulﬁte converted as
previously described.20 FFPE sections were deparafﬁnized in xylene by
submersion two times for 5min and in absolute ethanol three times for
5min. From each case, an hematoxylin and eosin-stained section was
annotated for cancerous and normal areas by an expert pathologist (DMB).
Using the annotated section as a guide and depending on estimated
tumor tissue size, one to six 5 mm FFPE sections were macro-dissected.23
DNA was extracted using the QIAamp DNA FFPE tissue kit (Qiagen, Hilden,
Germany) according to the manufacturer’s recommendation with the
Proteinase K digestion done overnight and ﬁnally the DNA eluted in
2 40 ml of elution buffer. In all, 120 ng of DNA was used in the bisulﬁte
conversion with the EpiTect Bisulﬁte kit (Qiagen) according to the
manufacturer’s instructions for DNA extracted from FFPE tissues.
PCR and pyrosequencing
HSPB1 (reference sequence NG_008995) and 500-bp upstream sequence
(Figure 1a), was searched with MethPrimer24 set at default parameters
(Figure 1b). Using PyroMark Assay Design v. 2.0.1.15 (Qiagen), assays 1–5
were designed to cover the ﬁrst four CpG islands, whereas it was not
possible to obtain a functioning assay for the ﬁfth island. Assay 6 was
designed in the third exon. All assays were designed to include three to six
CpG positions in as short amplicon as possible and a non-CpG cytosine
internal control. Due care was taken to avoid any primer overlapping CpG
dyads to prevent ampliﬁcation biases. To limit the costs, all assays were
initially run on a selected set of specimens (Figure 1c) and assay 5 on all
available tissues (Figure 3a). PCRs were performed using a converted DNA
equivalent of 1000 cells (assuming 6.6 pg DNA per diploid cell) from FFPE
tissues or 400 cells from frozen tissues employing the PyroMark PCR kit
(Qiagen) as previously described.20 Assay primers and annealing
temperatures are presented in Supplementary Table 1. Correct ampliﬁca-
tion was conﬁrmed by QIAxcel capillary electrophoresis instrument
(Qiagen). PyroGold reagents (Qiagen) were used for the pyrosequencing
reaction and the signal was analyzed using the PSQ 96MA system (Biotage,
Uppsala, Sweden).20 All runs contained standard curves as previously
described.20
Hsp-27 expression
The Hsp-27 expression in cell lines was demonstrated with western blot
and intensity was measured as previously described.22 The Hsp-27
expression data were available for the TAPG cohort as it was previously
evaluated by immunohistochemistry.2
Statistical analysis
All analyses were based on a pre-deﬁned statistical analysis plan, agreed
before analysis. Mean methylation of the investigated CpG positions within
each assay was used for all analysis. Methylation data were adjusted for
primer bias through re-scaling methylation measurements by the median
standard curve. When exploring prognostic potential, FFPE data were
modiﬁed by setting all DNAme values below 5% to 0, while remaining data
were left continuous. Modiﬁcation was done to lower the method noise on
the results; 5% value was used as it clearly separated all BPH from PCa.
Cuzick trend test was used to investigate the trend of methylation status
across the six assays. The Wilcoxon rank sum test was used for
comparisons of DNAme from different assays in BPH vs PCa. The Wilcoxon
and Cuzick trend tests were used to compare association of DNAme with
available clinical variables and HSP-27 expression. Univariate Cox propor-
tional hazards model was ﬁtted with each variable and the statistically
signiﬁcant variables were included in the multivariate Cox model. Six
missing extent of disease values were imputed by the median value of 1 to
avoid reducing of the sample size.25 All P-values are two-sided and
considered signiﬁcant if o0.05. Statistical analyses were performed in
Stata version 11 (StataCorp, College Station, TX, USA) and R version 2.12.2
Figure 1. Schematic overview of (a) the HSPB1 gene, (b) the CpG islands and the investigated sites and (c) the measurement of six methylation
assays. (a) Transcription factor-binding sites (TFBS) and TATA box are located within the 200-bp region upstream of the transcriptional start
site at position 156 (arrow). The HSPB1 gene, 1740-bp, and 500-bp upstream of the gene were searched with Methprimer, (b) identifying 5 CpG
islands (gray) located in (a): the first in the promoter region (black solid line), a second covering exon 1 (striped box), a third and fourth within
intron 1 (dotted line) and a fifth in exon 3. (b) CpG positions investigated by assay 1–6 are circled in the CpG map. (c) Median of methylation in
fresh frozen 10 BPH (circle) and 27 prostate cancer (PCa) (square) show the increasing separation between BPH and PCa going in 3’ direction,
differences between BPH and PCa were all significant by the Wilcoxon test with the maximum difference (Po0.0001) provided by assay 5. The
increase in DNAme across the six assays was highly significant (Po0.0001). The dashed line indicates 5% methylation.
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(Free Software Foundation, Boston, MA, USA). Graphpad Prism v5.03
(GraphPad Software, La Jolla, CA, USA) was used for the illustrations.
RESULTS
Methylation across the HSPB1 gene
Methylation of CpG islands in promoter, exon 1 and intron 1
increased in PCa but remained below 5% in BPH tissue (Figure 1c).
Assay 1 could not distinguish between BPH and PCa (P¼ 0.05).
Assay 2, covering transcription factor-binding sites,26 showed
some separation of these categories with a low median
methylation of 5% in PCa and 3% in BPH (P¼ 0.009). In assay 3,
interrogating CpG positions close to the TATA box (Figure 1b),27
the median methylation of PCa was 5% compared with 1%
methylation in BPH (P¼ 0.001). In intron 1, the median
methylation increased to 8% in assay 4 (P¼ 0.0004) and 28% in
assay 5 (Po0.0001) in PCa, whereas 0% was observed in BPH with
both assays (Figure 1c). In each PCa where DNAme measured high
with assay 5, an increasing trend in the 3’ direction was observed
with corresponding assays 1–4. Downstream of the CpG islands, in
exon 3, highest methylation was observed in both BPH and PCa
with median 52% and 68%, respectively, (P¼ 0.03; Figure 1c). As
the largest methylation difference between BPH and PCa was
observed with assay 5, it was further used to investigate both the
diagnostic and prognostic potential of DNAme.
Association between DNAme and protein expression
Expression of Hsp-27 and DNAme of HSPB1 were measured in
eight cell lines (Figure 2a). Highest DNAme was observed in exon 3
in all cell lines with LnCaP measuring lowest at 40% (Figure 2b).
Also, in LnCaP, highest expression of Hsp-27 was observed at 1.7-
fold compared with PNT2. Protein expression was lowest (0.6-fold)
in PC3M-3 and absent in VCaP. Although PC3M-3 was unmethy-
lated in CpG islands similar to PNT2, VCaP was the only cell line
where methylation was increasing and above 5% in assays 3–5.
DU145, PC3, PCM3 and ST3 displayed unmethylated CpG islands
and similar levels of expression to PNT2.
Wilcoxon test showed no association (P¼ 0.6) between DNAme
and Hsp-27 immunohistochemistry score in the FFPE tissues
(Supplementary Figure 1b).
Diagnostic potential of assay 5 in frozen and FFPE tissues
Methylation was successfully measured in 349 of 367 FFPE TAPG
cohort specimens, 29 of the 30 FFPE BPH and all available frozen
tissues. In the fresh frozen material, the median methylation was
14% in PCa and 1% in BPH (Po0.0001), whereas it was 5% in FFPE
PCa and 1% in FFPE BPH (Po 0.0001; Figure 3a). The seemingly
lower methylation in FFPE comparing with frozen PCa tissues was
not signiﬁcant (P¼ 0.14). Using 5% as a predeﬁned methylation
threshold to minimize false-positive results, diagnostic sensitivity
in the fresh and FFPE material was 58% (95% conﬁdence interval
(CI) 43–72%) and 50% (95% CI 45–55%), respectively, with cor-
responding speciﬁcity 100% (95% CI 88–100%) in both material
types (Figure 3b).
Prognostic potential of assay 5
The median age in the TAPG cohort was 70.5 years (interquartile
range 67.3 to 73.2) and median follow-up was 9.5 years with up to
a maximum of 20 years. In all, 91 out of 349 patients died of PCa.
First, the relationship between HSPB1 DNAme and all available
variables was investigated (Supplementary Figure 1) showing a
signiﬁcant association with Gleason score (P¼ 0.003) and extent of
disease (Po0.0001) but not age (P¼ 0.2), PSA (P¼ 0.07) or HSP-27
immunohistochemistry score.
Figure 2. Heat shock protein 27 (Hsp-27) expression and gene
methylation in eight investigated cell lines. (a) Mean Hsp-27 generic
expression (fold difference) relative to the immortalized prostate
epithelial cell line PNT2 ± 1 s.d. was measured by western blot.
(b) The methylation of six investigated regions in corresponding cell
lines are shown in grayscale.
Figure 3. The diagnostic potential of HSPB1 DNA methylation
(DNAme). (a) Methylation of HPSB1 was significantly (Po0.0001)
higher in prostate cancer (PCa) tissue comparing with BPH in both
fresh frozen and formalin-fixed paraffin-embedded (FFPE) samples.
The dotted line shows 5% methylation. (b) In order to visualize the
diagnostic efficacy of HPSB1 methylation measured in the FFPE
tissues in absence of an arbitrary cutoff value, the data were
summarized using a receiver operating characteristic curve (ROC).
Based on the sensitivity and specificity, highest possible speci-
ficity (100%) was obtained at cutoff 5%, with corresponding
sensitivity 50%.
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In the univariate Cox model, prostate speciﬁc death was
signiﬁcantly associated to Gleason score, extent of disease
(proportion of TURP chips with disease), PSA level and HSPB1
DNAme level (Table 1). The hazard ratio was 1.77 (95% CI 1.13–
2.79) per 50% increase in DNAme.
All signiﬁcant variables in the univariate model were included in
the multivariate analysis as well as all interactions between HSPB1
DNAme and all clinical variables. A signiﬁcant negative interaction
was only found for Gleason score and HSPB1 DNAme with hazard
ratio 0.98 (95% CI 0.97–0.99) and P¼ 0.014. To illustrate this
interaction, DNAme was stratiﬁed by Gleason score and endpoint
status (Figure 4). Comparison of a model including HSPB1 DNAme
and a model with only clinical variables showed that HSPB1
DNAme signiﬁcantly improved the ability to predict prostate spe-
ciﬁc death (Dw2¼ 6.673, df¼ 2, P¼ 0.036; Supplementary Table 2).
DISCUSSION
The data from our current study support, in part, the original
hypothesis by demonstrating a relationship between methylation
of HSPB1 and the aggressive phenotype within a cohort of men
with poor clinical outcome but low Gleason score (P¼ 0.014).
DNAme increased in the 30 direction of HSPB1, beginning with
CpG positions covering the regulatory sequences in PCa but not in
BPH (Figure 1). Previously, it had been reported1,2 that progression
of in situ neoplasia to frank malignancy is invariably accompanied
by decline of HSP-27 protein (Supplementary Figure 2). Thereafter,
subsequent development of invasive malignancy may be accom-
panied by re-expression of HSP-27 in the B30% of cases that are
universally aggressive.1,2,15 Nevertheless, this study did not reveal
a simple linear relationship between DNAme and reduced HSP-27
expression (Supplementary Figure 1). In seven human prostate cell
lines, DNAme of CpG islands waso10% (Figure 2), VCaP being the
only cell line exhibiting a similar gradual increase in DNAme across
the gene to that seen in PCa tissues. Also, VCaP was the only of
eight cell lines of varying malignancy that did not express Hsp-27
protein, supporting silencing of the gene by hypermethylation.
Hsp-27 expression was highest in LNCaP and showed decreased
methylation in exon 3 comparing with the other cell lines
(Figure 2). However, in PC3-M3, although the gene was not
methylated, its expression was decreased by some 50%. When
examined together, these data indicate a more complex regula-
tion of Hsp-27 protein levels in vivo than simply by DNAme alone.
Although, methylation was highest outside the CpG islands as
expected in both BPH and PCa, assay 6 was still able to distinguish
between the tissues (P¼ 0.03). This could be a reﬂection of a
generalized cellular defense attempt to inhibit expression of
destabilizing genes through a global increase of de novo
methylation in PCa.28 In addition, the methylation difference
Table 1. The summary statistics of clinical and pathological variables and the univariate and multivariate Cox models
Variable N (DPCa) Univariate analysis Multivariate analysis
HR (95% CI) w2a P-value HR (95% CI) w2 P-value
Modified HSPB1b 349 (91) 1.12 (1.02, 1.23) 5.4 0.02 1.18 (0.98, 1.41) 3.2 0.075
Age 1.69 (0.94, 3.05) 3.5 0.06
p65 61 (13)
465 288 (78)
Gleason score 3.04 (2.35, 3.93) 79.3 o0.0001 2.36 (1.65, 3.37) 22.3 o 0.0001
o7 183 (18)
¼ 7 78 (24)
47 88 (49)
PSA score 2.00 (1.71, 2.34) 75.1 o0.0001 1.49 (1.25, 1.78) 19.8 o 0.0001
p4 130 (12)
44–10 74 (11)
410–25 71 (25)
425–50 51 (25)
450–100 23 (18)
PCa in biopsy (%) 1.85 (1.60, 2.15) 73.1 o0.0001 1.35 (1.13, 1.61) 11.1 0.001
p6 104 (10)
46–20 91 (12)
420–40 53 (16)
440–75 42 (15)
475–100 59 (38)
Interaction term (HSPB1
DNAme  Gleason score)
349 (91) 0.98 (0.97, 0.99) 6.1 0.014
Abbreviations: CI, confidence interval; DNAme, DNA methylation; DPCa, died of PCa; HR, hazard ratio; PCa, prostate cancer.
aOne-degree freedom.
bContinuous methylation per 10% change.
Figure 4. DNA methylation (DNAme) in patients who died (white
box) of prostate cancer and patients alive or censored at the end of
the study (shaded box) was stratified by Gleason score. In the low
Gleason score group, higher median methylation (6%) was observed
in patients who died than in patients alive or censored at the end of
the study (median DNAme¼ 0%). In the high Gleason score group,
the reverse was observed with median methylation 8% vs 0%.
Whiskers of the boxplot mark the 5th and 95th percentiles, the box
25th percentile, median and 75 percentile, whereas extreme values
are shown by ().
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between BPH and PCa was most pronounced in the ﬁrst intron of
HSPB1 suggesting that, for diagnostic purposes, it may be valuable
to assess methylation in regions outside the promoter. So far,
substantial research efforts have shown that increased DNAme of
the promoters of genes such as GSTP1, RARB, APC, TIG1 can be
detected in PCa biopsies as well as bodily ﬂuids and may be useful
for early diagnosis, although none have been validated for routine
clinical use.29,30 Diagnostic potential of HSPB1 methylation using a
5% methylation cutoff, was comparable in frozen and FFPE tissues
with 50–58% sensitivity and 100% speciﬁcity (Figure 3). Although
methylation was measured in the intron alone, we believe that
measuring methylation levels in the other regions would not have
yielded different results because the initial data showed an
increasing trend for methylation in the 3’ direction of the gene.
The prognostic value of HSPB1 DNAme was indicated by both
univariate and multivariate models (Table 1). In the multivariate
analysis, signiﬁcant negative interaction observed between
DNAme and Gleason score suggests that the increased methyla-
tion of HSPB1 is a marker of poor outcome in men with low
Gleason score who would previously have been regarded as being
at low risk (Figure 4). The interaction term formed a ﬁnal model
with PSA, extent of disease and Gleason score and was stronger
than a model excluding DNAme (P¼ 0.036). Therefore, measuring
HSPB1 DNAme adds valuable information when assessing an
individual patient’s risk of death due to PCa. Our data are in line
with the previously observed absence of HSP-27 protein in
patients with low Gleason score but aggressive invasive PCa.1 In
addition, the stratiﬁed hazard ratio over time showed that HSPB1
methylation is useful in identifying men at high risk of developing
aggressive disease 7 years after the diagnosis (Supplementary
Figure 3). This may mirror that the men that are at high risk but
with low Gleason score would have a longer life expectancy when
compared with those with high Gleason score. Although exciting,
the interaction found between methylation and Gleason score
was based only on a small number of patients (Figure 4) and
validation in a larger set of samples is currently underway. A
potential limitation to our study is the use of TURP specimens.
Although TURP is not the standard modality for the diagnosis of
PCa, analysis of these samples has allowed us to assemble a
unique cohort with up to 20 years of clinical follow-up. We believe
that changes in HSPB1 are intrinsic to PCa carcinogenesis and may
be a driving process within this malignancy. If this is further
substantiated, then assessment of HSPB1 methylation is expected
to yield similar data in prostate needle core biopsies, although the
terms of the risk equation may change to reﬂect the different
specimen types.
In conclusion, HSPB1 is essentially unmethylated in BPH but
with increasing neoplastic changes through to PCa, the gene
becomes increasingly methylated, proceeding from the promoter
in a 3’ direction. In PCas with low Gleason score, higher methy-
lation within the HSPB1 gene independently identiﬁes patients
with poor clinical outcome and hence is an objective biomarker
identifying the immediate need for active intervention in the
clinical management of this cohort of patients.
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